Lefitolimod vs Standard of Care (SOC) for Patients with Metastatic Colorectal Cancer (mCRC) Responding to First-Line Therapy: Results from IMPALA Trial (DKK 2020) - Jan 25, 2020 - Abstract #1016; Pres time: Feb 19, 2020; 03:45 PM - 03:57 PM; Location: New York 2; "Patients with an objective response to first-line induction therapy (5FU/FA or CAPE, plus OX or IRI, alone or plus antiVEGF or antiEGFR) were randomized to receive either lefitolimod monotherapy (experimental arm) or local SOC (control arm). Lefitolimod did not show superiority to SOC as a single agent maintenance treatment in patients with mCRC. Limited add-on toxicity confirmed the favorable safety and tolerability profile of lefitolimod. Hence, and given its mode of action, lefitolimod will be evaluated in combination with other anti-cancer immunotherapies."
Clinical • Late-breaking abstract
|
|
Dirk Arnold1 ; Depenbusch Reinhard2 ; Meinolf Karthaus3 ; Claus Bolling4 ; Susanna Hegewisch-Becker5 ; Ramon Salazar6 ; Alberto Sobrero7 ; Michel Ducreux8 ; Eric Van Cutsem9 ; Werner Schweithauer10; Christophe Tournigand11; Daniela Schleif12; Mireille Starke12; Matthias Baumann12; Erol Wiegert12; Manuel Schmidt12; David Cunningham13
|